natgillin/translations-raw huggingface dataset:
Andre oplysninger om Helicobacter Test INFAI Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Helicobacter Test INFAI til INFAI, Institut für biomedizinische Analytik & NMR-Imaging GmbH den 14. august 1997. 
The European Commission granted a marketing authorisation valid throughout the European Union for Helicobacter Test INFAI to INFAI, Institut für biomedizinische Analytik & NMR-Imaging GmbH on 14 August 1997.
Det aktive stof i Helicobacter Test INFAI, 13C-urea, er det naturlige kemikalie urea, der er blevet mærket med kulstof-13 (13C). 
The active substance in Helicobacter Test INFAI, 13C-urea, is the natural chemical urea that has been labelled with carbon-13 (13C).
De nærmere oplysninger om, hvordan testen udføres, fremgår af indlægssedlen. 
For full information on how the test is carried out, see the Package Leaflet.
EUROPÆISK OFFENTLIG VURDERINGSRAPPORT (EPAR) HELICOBACTER TEST INFAI EPAR - sammendrag for offentligheden 
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) HELICOBACTER TEST INFAI EPAR summary for the public
Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Helicobacter Test INFAI er større end risiciene, når lægemidlet anvendes til in vivo-diagnosticering af gastroduodenal H. pylori-infektion hos voksne, hos unge, der er disponeret for peptisk ulcus, samt hos børn i alderen 3-11 år til vurdering af, hvor vellykket eradikationsbehandlingen er, eller når der ikke kan foretages invasive undersøgelser, eller når invasive undersøgelser giver resultater, der ikke stemmer overens. 
The Committee for Medicinal products for Human Use (CHMP) decided that Helicobacter Test INFAI's benefits are greater than its risks for the in vivo diagnosis of gastroduodenal H. pylori infection in adults, adolescents who are likely to have peptic ulcer disease, and children aged three to 11 years for the evaluation of the success of eradication treatment, or when invasive tests cannot be performed, or when there are discordant results arising from invasive tests.
H. pylori er en bakterie, der spiller en rolle i forbindelse med sygdomme som dyspepsi (halsbrand, oppustethed og kvalme), gastritis (betændelse i maven) og peptisk ulcus (mavesår eller sår på tolvfingertarmen). 
H. pylori is a bacterium that is a factor in diseases such as dyspepsia (heartburn, bloating and nausea), gastritis (inflammation of the stomach), and peptic ulcer disease (ulcers in the stomach or the duodenum).
I alle undersøgelser stemte resultaterne af testen udført med Helicobacter Test INFAI i over 95 % af tilfældene overens med resultaterne fra endoskopien med den histologiske undersøgelse. 
In all studies, the results of the test done using Helicobacter Test INFAI agreed with the results obtained with the endoscopy and histology in over 95% of cases.
Patienten skal i forbindelse med testen indsamle fire prøver, to før indtagelse af Helicobacter Test INFAI og to bagefter. 
To carry out the test, the patient must collect four samples, two before taking Helicobacter Test INFAI and two thereafter.
Patienterne fik i alle undersøgelser foretaget en endoskopi med en histologisk undersøgelse (en sonde føres ind i maven for at tage en prøve, og prøven bliver herefter analyseret) samt en test af udåndingsluften med Helicobacter Test INFAI, og resultaterne af de to undersøgelser blev sammenlignet. 
In all studies, patients underwent an endoscopy and histology (when a probe is inserted in the stomach to take a sample and the sample is then analysed) as well as a breath test with Helicobacter Test INFAI, and the results of the two tests were compared.
Helicobacter Test INFAI er en test af udåndingsluften: der tages prøver af udåndingsluften, som herefter sendes til analyse på et specialiseret laboratorium. 
Helicobacter Test INFAI is a breath test: breath samples are collected, which are then sent out for analysis to a specialised laboratory.
Testen kan kun anvendes til børn, når det ikke er muligt at foretage invasive undersøgelser (udtagning af en prøve fra maven ved hjælp af en sonde), hvis de invasive undersøgelser har givet tvivlsomme resultater, eller for at kontrollere, at H. pylori er blevet elimineret efter en specifik behandling mod infektionen. 
It can only be used in children when invasive tests (taking a sample from the stomach using a probe) cannot be carried out or have given questionable results, or to check that H. pylori has been eliminated after a specific treatment to clear up the infection.
Helicobacter Test INFAI kan anvendes til at teste voksne, unge, der er disponeret for peptisk ulcus, og børn i alderen 3-11 år. 
Helicobacter Test INFAI can be used to test adults, adolescents who are likely to have peptic ulcer disease, and children aged three to 11 years.
Når patienten tager Helicobacter Test INFAI, nedbrydes 13C-ureaet i testen af H. pylori til kuldioxid, der også indeholder 13C. 
When the patient takes Helicobacter Test INFAI, the 13C-urea contained in the test is broken down by H Pylori into carbon dioxide that also contains 13C.
Helicobacter Test INFAI må ikke anvendes til patienter, som har eller kan have en gastrisk infektion (maveinfektion) eller atrofisk gastritis (maveinfektion, der medfører en nedbrydning af mavesækkens slimhinde), da disse tilstande kan påvirke testen af udåndingsluften. 
Helicobacter Test INFAI should not be used in patients who have, or may have gastric (stomach) infection or atrophic gastritis (stomach inflammation that causes the breakdown of the stomach lining), as these might interfere with the breath test.
Helicobacter Test INFAI anvendes til diagnosticering af infektion med Helicobacter pylori i maven og tolvfingertarmen (den del af tarmen, som ligger lige under mavesækken). 
Helicobacter Test INFAI is used to diagnose Helicobacter pylori infection in the stomach and duodenum (the part of the gut just below the stomach).
De fik alle 75 mg 13C-urea, med undtagelse af 204 børn under 11 år, som fik 45 mg. En af undersøgelserne med voksne blev udført hos patienter, som allerede havde fået antibiotika til behandling af deres infektion. 
children under the age of 11 who received 45 mg. One of the studies in adults was carried out in patients after they had received antibiotics to treat their infection.
Udvalget anbefalede udstedelse af markedsføringstilladelse for Helicobacter Test INFAI. 
The Committee recommended that Helicobacter Test INFAI be given marketing authorisation.
Den fuldstændige EPAR om Helicobacter Test INFAI findes her. 
The full EPAR for Helicobacter Test INFAI is available here.
Helicobacter Test INFAI er en diagnostisk test. 
Helicobacter Test INFAI is a diagnostic test.
H. pylori indeholder enzymer, der kaldes ureaser. 
H. pylori contain enzymes called ureases that make it able to break down urea into carbon dioxide, which is then removed in the breath.
Hvilken risiko er der forbundet med Helicobacter Test INFAI? 
What is the risk associated with Helicobacter Test INFAI?
Hvorfor blev Helicobacter Test INFAI godkendt? 
Why has Helicobacter Test INFAI been approved?
Hvad er Helicobacter Test INFAI? 
What is Helicobacter Test INFAI?
Først skal patienten indsamle to prøver af udåndingsluften ved at benytte de rør eller poser, der følger med Helicobacter Test INFAI. 
The patient should not eat for at least six hours, preferably overnight, before taking the test. Firstly, the patient collects two breath samples, using the tubes or bags supplied with Helicobacter Test INFAI.
Hvordan blev Helicobacter Test INFAI undersøgt? 
How has Helicobacter Test INFAI been studied?
Hvad anvendes Helicobacter Test INFAI til? 
What is Helicobacter Test INFAI used for?
Hvordan anvendes Helicobacter Test INFAI? 
How is Helicobacter Test INFAI used?
Hvilken fordel viser undersøgelserne, at der er ved Helicobacter Test INFAI? 
What benefit has Helicobacter Test INFAI shown during the studies?
Hvordan virker Helicobacter Test INFAI? 
How does Helicobacter Test INFAI work?
Hyppighed defineres i henhold til følgende konvention: almindelig (>1/100 til <1/10); ikke almindelig (>1/1.000 til <1/100); sjælden (>1/10.000 til <1/1.000); meget sjælden <1/10.000), ikke kendt (kan ikke estimeres ud fra forhåndenværende data). 
Their frequency is defined using the following conventions: common ( 1/100 to <1/10); uncommon ( 1/1,000 to < 1/100); rare (1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
• bør du fortælle din læge, hvis du skal have foretaget en planlagt operation (også hos tandlægen). 
• You should tell your doctor if a surgery (including dental) is planned.
Indehaveren af markedsføringstilladelsen skal sikre at pharmacovigilance-systemet, som er beskrevet i Modul 1.8.1 i markedsføringstilladelsen, er på plads og fungerer, før og mens produktet markedsføres. 
The MAH must ensure that the system of pharmacovigilance, presented in Module 1.8.1 of the Marketing Authorisation, is in place and functioning before and whilst the product is on the market.
For pakningsstørrelsen med 28x1 tabletter kan du tjekke dagen, hvor du sidst tog en tablet ved at kigge på kalenderen printet på blisterpakningen. 
For the 28x1 tablets pack size, you can check the day on which you last took the tablet by referring to the calendar printed on the blister.
ACTIVE-A-studiet inkluderede patienter, som ikke kunne behandles med VKA, fordi de ikke var i stand til eller uvillige til at få behandlingen. 
The ACTIVE-A study included patients who could not receive VKA therapy because they were unable or unwilling to receive the treatment.
Den gennemsnitlige CHADS2-score var 2,0 (interval 0-6). 
The mean CHADS2 score was 2.0 (range 0-6).
Lægemidler, der er forbundet med risiko for blødning: Der er en øget risiko for blødning på grund af mulig additiv virkning. 
Medicinal products associated with bleeding risk: There is an increased risk of bleeding due to the potential additive effect.
Clopidogrel og den cirkulerende (inaktive) hovedmetabolit binder reversibelt in vitro til humane plasmaproteiner (henholdsvis 98 % og 94 %). 
Clopidogrel and the main circulating (inactive) metabolite bind reversibly in vitro to human plasma proteins (98 % and 94 % respectively).
Yderligere oplysninger om dette lægemiddel er tilgængelig på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu/. 
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.
Bivirkninger, der opstod enten under de kliniske studier, eller der spontant blev indberettet, er beskrevet i tabellen nedenfor. 
Adverse reactions that occurred either during clinical studies or that were spontaneously reported are presented in the table below.
Visse andre lægemidler kan påvirke brugen af Clopidogrel Teva Pharma eller omvendt. 
Some other medicines may influence the use of Clopidogrel Teva Pharma or vice versa.
Dato for første markedsføringstilladelse: 21. september 2009 Dato for seneste fornyelse: 8. maj 2014 
Date of latest renewal: 8 May 2014
Blodplader er meget små bestanddele i blodet, og de klumper sig sammen, når blodet størkner. 
Platelets are very small structures in the blood, which clump together during blood clotting.
Patienter, der tidligere har udviklet en allergisk og/eller hæmatologisk reaktion over for en thienopyridin, kan have en øget risiko for at udvikle den samme eller en anden reaktion over for en anden thienopyridin. 
Patients who had developed a previous monitored allergic reaction and/or haematological reaction to one thienopyridine may have an increased risk of developing the same or another reaction to another thienopyridine.
Forebyggelse af aterotrombotiske hændelser 
Prevention of atherothrombotic events
Forekomsten af alvorlige tilfælde var ens for clopidogrel og ASA. 
The incidence of severe cases was similar for clopidogrel and ASA.
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenien TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Tyskland Pharmachemie B.V., Swensweg 5, 2031 GA Haarlem, Holland 
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany Pharmachemie B.V., Swensweg 5, 2031 GA Haarlem, The Netherlands
Hvis du får langvarige blødninger, mens du tager Clopidogrel Teva Pharma Hvis du skærer dig eller kommer til skade, kan det tage lidt længere end normalt, før blødningen stopper. 
If you experience prolonged bleeding when taking Clopidogrel Teva Pharma If you cut or injure yourself, it may take slightly longer than usual for bleeding to stop.
Du skal fortsætte med at tage Clopidogrel Teva Pharma, så længe som din læge udskriver det til dig. 
You should take Clopidogrel Teva Pharma for as long as your doctor continues to prescribe it.
Hvis du har taget for mange Clopidogrel Teva Pharma Kontakt din læge eller nærmeste skadestue, på grund af den øgede risiko for blødning. 
If you take more Clopidogrel Teva Pharma than you should Contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding.
Du bør være blevet informeret om, at ”orale antikoagulantia” er mere effektive mod denne sygdom end acetylsalicylsyre eller kombinationen af Clopidogrel Teva Pharma og acetylsalicylsyre. 
You should have been told that ‘oral anticoagulants' are more effective than acetylsalicylic acid or the combined use of Clopidogrel Teva Pharma and acetylsalicylic acid for this condition.
De klinisk relevante bivirkninger observeret i CAPRIE-, CURE-, CLARITY-, COMMITog ACTIVE-A-studierne beskrives nedenfor. 
The clinically relevant adverse reactions observed in the CAPRIE, CURE, CLARITY, COMMIT and ACTIVE-A studies are discussed below.
Der er gennemført en række andre kliniske studier med clopidogrel og anden samtidig medicinering for at undersøge muligheden for farmakodynamisk og farmakokinetisk interaktion. 
Other medicinal products: A number of other clinical studies have been conducted with clopidogrel and other concomitant medicinal products to investigate the potential for pharmacodynamic and pharmacokinetic interactions.
Hvis du bliver gravid, mens du tager Clopidogrel Teva Pharma, skal du omgående kontakte din læge, da det frarådes at tage clopidogrel, mens du er gravid. 
If you become pregnant while taking Clopidogrel Teva Pharma, consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant.
Hvis du har glemt en dosis af Clopidogrel Teva Pharma, men kommer i tanke om det i løbet af 12 timer, skal du omgående tage tabletten og dernæst tage den næste tablet til sædvanlig tid. 
If you forget to take a dose of Clopidogrel Teva Pharma, but remember within 12 hours of your usual time, take your tablet straightaway and then take your next tablet at the usual time.
Ved at forhindre denne sammenklumpning nedsætter medicinen, der opløser blodpropper, risikoen for, at der dannes blodpropper (en proces, der kaldes trombose). 
By preventing this clumping, antiplatelet medicinal products reduce the chances of blood clots forming (a process called thrombosis).
Sikkerheden og effekten af clopidrogrel er blevet evalueret i 5 dobbeltblindede studier, der omfattede mere end 88.000 patienter: CAPRIE-studiet, hvor clopidogrel sammenlignes med ASA, og CURE, CLARITY, COMMIT- og ACTIVE-A-studierne, hvor clopidogrel sammenlignes med placebo, og hvor begge lægemidler gives i kombination med ASA eller anden standardterapi. 
The safety and efficacy of clopidogrel have been evaluated in 5 double-blind studies involving over 88,000 patients: the CAPRIE study, a comparison of clopidogrel to ASA, and the CURE, CLARITY, COMMIT and ACTIVE-A studies comparing clopidogrel to placebo, both medicinal products given in combination with ASA and other standard therapy.
EU/1/09/561/001 7 filmovertrukne tabletter EU/1/09/561/002 14 filmovertrukne tabletter EU/1/09/561/003 28 filmovertrukne tabletter EU/1/09/561/004 30 filmovertrukne tabletter EU/1/09/561/005 50 filmovertrukne tabletter EU/1/09/561/006 56 filmovertrukne tabletter EU/1/09/561/007 84 filmovertrukne tabletter EU/1/09/561/008 90 filmovertrukne tabletter EU/1/09/561/009 100 filmovertrukne tabletter EU/1/09/561/010 28x1 filmovertrukne tabletter EU/1/09/561/011 50x1 filmovertrukne tabletter 
EU/1/09/561/001 7 film-coated tablets EU/1/09/561/002 14 film-coated tablets EU/1/09/561/003 28 film-coated tablets EU/1/09/561/004 30 film-coated tablets EU/1/09/561/005 50 film-coated tablets EU/1/09/561/006 56 film-coated tablets EU/1/09/561/007 84 film-coated tablets EU/1/09/561/008 90 film-coated tablets EU/1/09/561/009 100 film-coated tablets EU/1/09/561/010 28x1 film-coated tablets EU/1/09/561/011 50x1 film-coated tablets
Din læge bør have udskrevet Clopidogrel Teva Pharma plus acetylsalicylsyre, hvis duikke må tage ”orale antikoagulantia”, og du ikke har en risiko for alvorlig blødning. 
Your doctor should have prescribed Clopidogrel Teva Pharma plus acetylsalicylic acid if you cannot take ‘oral anticoagulants' and you do not have a risk of major bleeding
MINDSTEKRAV TIL MÆRKNING PÅ BLISTER ELLER STRIP BLISTERKORT (28x1 filmovertrukne tabletter) 
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER (28x1 film-coated tablets)
ACTIVE-A-studiet (N = 7.554) var et multicenter, randomiseret, dobbeltblindt, placebokontrolleret studie, som sammenlignede clopidogrel 75 mg/dag + ASA (N = 3.772) med placebo + ASA (N = 3.782). 
The ACTIVE-A study (N=7,554) was a multicenter, randomized, double-blind, placebo-controlled study which compared clopidogrel 75 mg/day + ASA (N=3,772) to placebo + ASA (N=3,782).
CYP2C19*1-allelen svarer til en fuldt funktionel metabolisme, mens CYP2C19*2- og CYP2C19*3allelerne ikke er funktionelle. 
The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and CYP2C19*3 alleles are nonfunctional.
In vitro-studier har vist, at den øgede eksponering for repaglinid skyldes hæmning af CYP2C8 ved glukuronidmetabolitten af clopidogrel. 
In vitro studies have shown the increase in repaglinide exposure is due to inhibition of CYP2C8 by the glucuronide metabolite of clopidogrel.
Den anbefalede ASA-dosis var 75 til 100 mg/dag. 
The recommended dose for ASA was 75 to 100 mg/day.
I CURE var der ikke overrepræsentation af større blødninger med clopidogrel plus ASA inden for 7 dage efter koronar bypassoperation hos patienter, der indstillede behandlingen mere end 5 dage før indgrebet. 
In CURE, there was no excess in major bleeds with clopidogrel plus ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery.
Farmakoterapeutisk klassifikation: Antitrombotiske midler, trombocytfunktionshæmmende midler eksklusive heparin, ATC-kode: B01AC-04. 
Pharmacotherapeutic group: Antithrombotic agents, platelet aggregation inhibitors excl. heparin, ATC Code: B01AC-04.
Perforerede enhedsdosisblistere af OPA/Al/PVC-Al indeholdende 28x1 og 50x1 filmovertrukne tabletter. 
Perforated unit dose blister of OPA/Al/PVC-Al containing 28x1 and 50x1 film-coated tablets in the box.
Den almindeligste bivirkning, indberettet med Clopidogrel Teva Pharma er blødning. 
The most common side effect reported with Clopidogrel Teva Pharma is bleeding.
• Risikostyringsprogram 
• Risk Management Plan (RMP)
Advarsler og forsigtighedsregler Hvis nogen af følgende situationer gælder for dig, skal du oplyse det til din læge, før du tager Clopidogrel Teva Pharma: 
Warnings and precautions If any of the situations mentioned below apply to you, you should tell your doctor before taking Clopidogrel Teva Pharma:
Hos de patienter, som alene indgik i studiet på grund af et nyligt myokardieinfarkt, lå clopidogrel numerisk lavere, men ikke statistisk forskelligt fra ASA (RRR = 4,0 %, CI: -22,5 til 11,7 [p=0,639]). 
In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR =4.0%; CI: -22.5 to 11.7 [p=0.639]).
Undersøgelser i neutrofiltal, fald i trombocyttal * Information relateret til clopidogrel med hyppighed ”ikke kendt”. 
Bleeding time prolonged, neutrophil count decreased, platelet count decreased * Information related to clopidogrel with frequency “not known”.
Gastrointestinal og retroperitoneal blødning med dødelig udgang, pancreatitis, colitis (inklusive ulcerøs eller forstoppelse, flatulens lymfocytisk colitis), stomatitis 
Gastrointestinal and retroperitoneal haemorrhage with fatal outcome, pancreatitis, colitis (including ulcerative or lymphocytic colitis), stomatitis
Trafik- og arbejdssikkerhed Det er usandsynligt at Clopidogrel Teva Pharma påvirker din evne til at køre eller betjene maskiner. 
Driving and using machines Clopidogrel Teva Pharma is unlikely to affect your ability to drive or to use machines.
Clopidogrel Teva Pharma indeholder clopidogrel og tilhører en lægemiddelgruppe, der kaldes blodfortyndende medicin. 
Clopidogrel Teva Pharma contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products.
I et dosiseskaleringsstudie med 86 nyfødte eller spædbørn op til 24 måneder med risiko for trombose (PICOLO) blev clopidogrel evalueret ved konsekutive doser på 0,01, 0,1 og 0,2 mg/kg til nyfødte og spædbørn og ved 0,15 mg/kg alene til nyfødte. 
In a dose escalation study of 86 neonates or infants up to 24 months of age at risk for thrombosis (PICOLO), clopidogrel was evaluated at consecutive doses of 0.01, 0.1 and 0.2 mg/kg in neonates and infants and 0.15 mg/kg only in neonates.
Derefter er den anbefalede dosis 1 Clopidogrel Teva Pharma-tablet på 75 mg daglig som beskrevet ovenfor. 
Then, the recommended dose is one 75 mg tablet of Clopidogrel Teva Pharma per day as described above.
7 filmovertrukne tabletter 14 filmovertrukne tabletter 28 filmovertrukne tabletter 30 filmovertrukne tabletter 50 filmovertrukne tabletter 56 filmovertrukne tabletter 84 filmovertrukne tabletter 90 filmovertrukne tabletter 100 filmovertrukne tabletter 28x1 filmovertrukne tabletter 50x1 filmovertrukne tabletter 
7 film-coated tablets 14 film-coated tablets 28 film-coated tablets 30 film-coated tablets 50 film-coated tablets 56 film-coated tablets 84 film-coated tablets 90 film-coated tablets 100 film-coated tablets 28x1 film-coated tablets 50x1 film-coated tablets
PolyvinylalkoholTitandioxid (E171) Rød jernoxid (E172) Gul jernoxid 
Polyvinyl alcohol Titanium dioxide (E171) Red iron oxide (E172) Yellow iron oxide (E172) Talc
• hvis du er allergisk over for clopidogrel eller et af de øvrige indholdsstoffer i dette lægemiddel 
• If you are allergic to clopidogrel or any of the other ingredients of this medicine (listed in section 6).
• skal du også straks fortælle det til din læge, hvis du udvikler en medicinsk tilstand (trombocytisk trombocytopenisk purpura eller TTP), der giver feber og blå mærker under huden, der kan fremstå som røde små prikker, med eller uden uforklarlig udtalt træthed, forvirring, gulfarvning af huden eller øjnene (gulsot) (se pkt. 
• You should also tell your doctor immediately if you develop a medical condition (also known as Thrombotic Thrombocytopenic Purpura or TTP) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4 ‘Possible side effects').
Bulløs dermatitis (toksisk epidermal nekrolyse, StevensJohnson syndrom, erythema multiforme), akut generaliseret eksantematøs pustulose (AGEP), angioødem, lægemiddelinduceret overfølsomhedssyndrom, medikamentelt udslæt med eosinofili og systemiske symptomer (DRESS), erytematøst eller eksfoliativt udslæt, urticaria, eksem, lichen planus 
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme, acute generalised exanthematous pustulosis (AGEP)), angioedema, drug-induced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), rash erythematous or exfoliative, urticaria, eczema, lichen planus